Eledon Pharmaceuticals, Inc.
ELDNNASDAQHealthcare● Active
$3.58
+$0.17(+4.99%)
Market Cap$214618469
P/E Ratio—
52W High$4.6
52W Low$1.35
Eledon Pharmaceuticals, Inc. (ELDN) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ELDN · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 13, 2026EPS Actual
-$0.16
Est. -$0.22 · +27.3%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 13, 2026
After Market Close
▲ Beat EPS🔥 5-Quarter EPS Beat Streak
ELDN reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$93.32
Rev. $1001.5B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$93.32
Rev. Est.$1001.5B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.19 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 13, 2026 | -$0.22 | -$0.16 | +27.3% | — | — | — |
| ▲ Q1 FY2026 | Mar 19, 2026 | -$0.20 | -$0.10 | +50.0% | — | — | — |
| ▲ Q4 FY2025 | Nov 14, 2025 | -$0.22 | -$0.21 | +4.5% | — | — | — |
| ▲ Q3 FY2025 | Aug 14, 2025 | -$0.23 | -$0.13 | +43.5% | — | — | — |
| ▲ Q2 FY2025 | May 14, 2025 | -$0.28 | -$0.08 | +71.4% | — | — | — |
| ▼ Q1 FY2025 | Mar 20, 2025 | -$0.32 | -$0.64 | -100.0% | $0.00B | — | — |
| ▼ Q4 FY2024 | Nov 12, 2024 | -$0.30 | -$0.32 | -6.7% | — | — | — |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.19
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 13, 2026Beat
EPS Actual
-$0.16
EPS Est.
-$0.22
EPS Surpr.
+27.3%
Revenue
—
Q1 FY2026
Mar 19, 2026Beat
EPS Actual
-$0.10
EPS Est.
-$0.20
EPS Surpr.
+50.0%
Revenue
—
Q4 FY2025
Nov 14, 2025Beat
EPS Actual
-$0.21
EPS Est.
-$0.22
EPS Surpr.
+4.5%
Revenue
—
Q3 FY2025
Aug 14, 2025Beat
EPS Actual
-$0.13
EPS Est.
-$0.23
EPS Surpr.
+43.5%
Revenue
—
Q2 FY2025
May 14, 2025Beat
EPS Actual
-$0.08
EPS Est.
-$0.28
EPS Surpr.
+71.4%
Revenue
—
Q1 FY2025
Mar 20, 2025Miss
EPS Actual
-$0.64
EPS Est.
-$0.32
EPS Surpr.
-100.0%
Revenue
$0.00B
Q4 FY2024
Nov 12, 2024Miss
EPS Actual
-$0.32
EPS Est.
-$0.30
EPS Surpr.
-6.7%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.21 | $-0.21 | $-0.21 | 1 |
| Q3 FY2027 | $-0.20 | $-0.20 | $-0.20 | 1 |
| Q2 FY2027 | $-0.21 | $-0.21 | $-0.21 | 1 |
| Q1 FY2027 | $-0.20 | $-0.20 | $-0.20 | 1 |
| Q4 FY2026 | $-0.18 | $-0.18 | $-0.18 | 1 |
| Q3 FY2026 | $-0.18 | $-0.18 | $-0.18 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 13, 2026 | +27.3% | $3.90 | $3.88 | -0.51% |
| ▲ Q1 FY2026 | Mar 19, 2026 | +50.0% | $3.00 | $2.85 | -5.00% |
| ▲ Q4 FY2025 | Nov 14, 2025 | +4.5% | $1.76 | $1.76 | +0.00% |
| ▲ Q3 FY2025 | Aug 14, 2025 | +43.5% | $2.60 | $2.60 | +0.00% |
| ▲ Q2 FY2025 | May 14, 2025 | +71.4% | $2.90 | $2.83 | -2.41% |
| ▼ Q1 FY2025 | Mar 20, 2025 | -100.0% | $3.56 | $3.44 | -3.37% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -6.7% | $4.96 | $4.82 | -2.82% |
| ▼ Q3 FY2024 | Aug 19, 2024 | -3.2% | $2.73 | $2.76 | +1.10% |
Q2 FY2026-0.51%
Report Date
May 13, 2026
EPS Beat/Miss
+27.3%
Price Before
$3.90
Price After
$3.88
Q1 FY2026-5.00%
Report Date
Mar 19, 2026
EPS Beat/Miss
+50.0%
Price Before
$3.00
Price After
$2.85
Q4 FY2025+0.00%
Report Date
Nov 14, 2025
EPS Beat/Miss
+4.5%
Price Before
$1.76
Price After
$1.76
Q3 FY2025+0.00%
Report Date
Aug 14, 2025
EPS Beat/Miss
+43.5%
Price Before
$2.60
Price After
$2.60
Q2 FY2025-2.41%
Report Date
May 14, 2025
EPS Beat/Miss
+71.4%
Price Before
$2.90
Price After
$2.83
Q1 FY2025-3.37%
Report Date
Mar 20, 2025
EPS Beat/Miss
-100.0%
Price Before
$3.56
Price After
$3.44
Q4 FY2024-2.82%
Report Date
Nov 12, 2024
EPS Beat/Miss
-6.7%
Price Before
$4.96
Price After
$4.82
Q3 FY2024+1.10%
Report Date
Aug 19, 2024
EPS Beat/Miss
-3.2%
Price Before
$2.73
Price After
$2.76
Avg Beat Reaction-1.58%
Avg Miss Reaction-1.70%
Beat Rate5 / 8 quarters
Largest Move-5.00% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ELDN ends December
Eledon Pharmaceuticals, Inc. (ELDN) most recently reported earnings on May 13, 2026 for Q2 FY2026, posting EPS of $-0.16 — beating the analyst consensus of $-0.22 by +27.3%. ELDN has beaten EPS estimates for 5 consecutive quarters. The next ELDN earnings date is expected around September 1, 2026.
Each quarter, investors track ELDN earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ELDN revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ELDN's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ELDN earnings · 5 questionsEledon Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. ELDN typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ELDN historically reports after market close (AMC).
ELDN earnings datewhen is ELDN earningsELDN next earnings datewhen does ELDN report earningsELDN earnings calendar
▸ Source: FMP · Eledon Pharmaceuticals, Inc. SEC filings · US GAAP · Eledon Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026